EP2403839A4 - Neurotrophin mimetics and uses thereof - Google Patents
Neurotrophin mimetics and uses thereofInfo
- Publication number
- EP2403839A4 EP2403839A4 EP10749395.9A EP10749395A EP2403839A4 EP 2403839 A4 EP2403839 A4 EP 2403839A4 EP 10749395 A EP10749395 A EP 10749395A EP 2403839 A4 EP2403839 A4 EP 2403839A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- neurotrophin mimetics
- neurotrophin
- mimetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15830609P | 2009-03-06 | 2009-03-06 | |
US16428209P | 2009-03-27 | 2009-03-27 | |
PCT/US2010/026372 WO2010102212A2 (en) | 2009-03-06 | 2010-03-05 | Neurotrophin mimetics and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2403839A2 EP2403839A2 (en) | 2012-01-11 |
EP2403839A4 true EP2403839A4 (en) | 2014-05-28 |
Family
ID=42710232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10749395.9A Withdrawn EP2403839A4 (en) | 2009-03-06 | 2010-03-05 | Neurotrophin mimetics and uses thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2403839A4 (en) |
JP (2) | JP2012519703A (en) |
CA (1) | CA2754570A1 (en) |
WO (1) | WO2010102212A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723328B2 (en) | 2005-04-15 | 2010-05-25 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
JP5863663B2 (en) | 2009-11-12 | 2016-02-16 | ファーマトロフィックス, インコーポレイテッド | Crystal forms of neurotrophin mimetic compounds and their salts |
US10273219B2 (en) | 2009-11-12 | 2019-04-30 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
CA2814540A1 (en) * | 2010-10-13 | 2012-04-19 | Horacio Uri Saragovi | Inhibitors of p75 receptor and their uses |
CA2886231A1 (en) * | 2012-09-27 | 2014-04-03 | Pharmatrophix, Inc. | Crystalline forms of neurotrophin mimetic compounds and their salts |
EP3504209A4 (en) * | 2016-08-25 | 2020-04-29 | Pharmatrophix Inc. | Methods and compounds for treating alcohol use disorders and associated diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113097A2 (en) * | 2005-04-15 | 2006-10-26 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
WO2008107365A1 (en) * | 2007-03-02 | 2008-09-12 | Medivir Ab | New compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2762315B1 (en) * | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | AMINO ACID DERIVATIVES INHIBITOR OF EXTRACELLULAR MATRIX METALLOPROTEASES AND TNF ALPHA RELEASE |
US6492380B1 (en) * | 1999-05-17 | 2002-12-10 | Queen's University At Kingston | Method of inhibiting neurotrophin-receptor binding |
OA12698A (en) * | 2001-07-11 | 2006-06-22 | Elan Pharm Inc | N-(3-amino-2-hydroxy-propyl)substituted alkylamidecompounds. |
CA2466284A1 (en) * | 2001-11-08 | 2003-05-15 | Elan Pharmaceuticals, Inc. | N, n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
-
2010
- 2010-03-05 CA CA2754570A patent/CA2754570A1/en not_active Abandoned
- 2010-03-05 WO PCT/US2010/026372 patent/WO2010102212A2/en active Application Filing
- 2010-03-05 JP JP2011553135A patent/JP2012519703A/en active Pending
- 2010-03-05 EP EP10749395.9A patent/EP2403839A4/en not_active Withdrawn
-
2015
- 2015-07-23 JP JP2015145503A patent/JP2016026142A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006113097A2 (en) * | 2005-04-15 | 2006-10-26 | The University Of North Carolina At Chapel Hill | Methods of facilitating cell survival using neurotrophin mimetics |
WO2008107365A1 (en) * | 2007-03-02 | 2008-09-12 | Medivir Ab | New compounds |
Also Published As
Publication number | Publication date |
---|---|
CA2754570A1 (en) | 2010-09-10 |
WO2010102212A3 (en) | 2011-03-31 |
EP2403839A2 (en) | 2012-01-11 |
WO2010102212A2 (en) | 2010-09-10 |
JP2012519703A (en) | 2012-08-30 |
JP2016026142A (en) | 2016-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL210804A (en) | Benzylidenehydrazides and uses thereof | |
HK1196358A1 (en) | Substituted pyridin-2-ones and pyridazin-3-ones -2--3- | |
HK1171440A1 (en) | Alpha helix mimetics and methods relating thereto | |
HK1156030A1 (en) | Alpha helix mimetics and methods relating thereto | |
IL205571A0 (en) | 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin | |
GB2456813B (en) | Diagnostic context construction and comparison | |
PL3222617T3 (en) | Psma-targeting compounds and uses thereof | |
ZA201200766B (en) | Barley and uses thereof | |
GB0914644D0 (en) | Novel agents and uses thereof | |
GB0916578D0 (en) | Polypeptides and uses thereof | |
EP2476717A4 (en) | Polyamide and polyamide composition | |
EP2483292A4 (en) | Variant lovd polypeptides and their uses | |
EP2383283A4 (en) | Noggin-derived peptide and use thereof | |
GB0916576D0 (en) | Polypeptides and uses thereof | |
EP2474555A4 (en) | Wnt10-derived peptide and use thereof | |
EP2471799A4 (en) | Rare-earth complex and uses thereof | |
EP2318438A4 (en) | Anti-p2x7 peptiden und epitopen | |
ZA201103456B (en) | Leukolectins and uses thereof | |
EP2291377A4 (en) | Imidazopyrimidinones and uses thereof | |
EP2247601A4 (en) | Thiazopyrimidinones and uses thereof | |
EP2403839A4 (en) | Neurotrophin mimetics and uses thereof | |
GB0912744D0 (en) | Methods and uses | |
EP2285827A4 (en) | Peptides and uses thereof | |
HK1165106A1 (en) | Function unit and control center | |
EP2450374A4 (en) | Peptide and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20111006 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140428 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 403/04 20060101ALI20140422BHEP Ipc: A61K 31/4164 20060101ALI20140422BHEP Ipc: A61K 31/5375 20060101ALI20140422BHEP Ipc: A61K 31/522 20060101ALI20140422BHEP Ipc: A61K 31/5377 20060101ALI20140422BHEP Ipc: A61P 25/00 20060101ALI20140422BHEP Ipc: C07D 473/02 20060101ALI20140422BHEP Ipc: C07D 265/06 20060101AFI20140422BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Owner name: U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF V Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LONGO, FRANK, M. Inventor name: MASSA, STEPHEN M. |
|
17Q | First examination report despatched |
Effective date: 20150713 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160126 |